Eli Lilly to strengthen biotechnology capabilities
The current investment will ramp up the company’s R&D of multi-specific therapeutics. Eli Lilly intends to recruit biochemist and biologists to support its R&D for multi-specific drugs that
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).
Tibotec will be responsible for the formulation, manufacturing, registration, distribution and commercialization of the cobicistat and Prezista fixed-dose combination worldwide. Gilead is responsible to develop, manufacture and commercialize
Using Xerox’s Communication and Marketing Services, Medco provides 65 million members the ability to personalize their prescription drug management information and communication delivery channels. This multi-channel communications approach
Sherpa Clinical Packaging provides clinical trial material management services, including packaging, labeling, distribution and returns reconciliation, for pharmaceutical, biotechnology, medical device, in-vitro diagnostics and dietary supplement companies. The